Reply to Rappaport : Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.
作者信息
Dutt Tina, Simcox David, Downey Colin, McLenaghan Daniella, King Charlotte, Gautam Manish, Lane Steven, Burhan Hassan
机构信息
Liverpool University Hospitals National Health Service Foundation Trust Liverpool, United Kingdom.
Liverpool Clinical Laboratories Liverpool, United Kingdom and.
出版信息
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1733-1734. doi: 10.1164/rccm.202007-2913LE.
Abstract
摘要
相似文献
1
Reply to Rappaport : Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1733-1734. doi: 10.1164/rccm.202007-2913LE.
2
Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19.
Am J Respir Crit Care Med. 2020 Dec 15;202(12):1731-1733. doi: 10.1164/rccm.202006-2511LE.
3
Intermediate dose thromboprophylaxis in SARS-CoV-2 related venous thrombo embolism.
Eur J Intern Med. 2021 Jun;88:141-143. doi: 10.1016/j.ejim.2021.03.025. Epub 2021 Mar 26.
4
Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate.
Medicina (Kaunas). 2020 Sep 27;56(10):506. doi: 10.3390/medicina56100506.
5
[Recommendations for the use of thromboprophylaxis in hospitalized patients with COVID-19 in Argentina].
Medicina (B Aires). 2020;80 Suppl 3:65-66.
6
Management of perioperative thromboprophylaxis for surgery following COVID-19: an expert-panel survey.
Br J Anaesth. 2021 Oct;127(4):e143-e145. doi: 10.1016/j.bja.2021.06.041. Epub 2021 Jul 9.
7
Venous thromboembolism in COVID-19: systematic review of reported risks and current guidelines.
Swiss Med Wkly. 2020 Jun 21;150:w20301. doi: 10.4414/smw.2020.20301. eCollection 2020 Jun 15.
8
Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial".
Blood Transfus. 2020 May;18(3):239-240. doi: 10.2450/2020.0116-20.
9
Pulmonary Embolism or Pulmonary Thrombosis in COVID-19? Is the Recommendation to Use High-Dose Heparin for Thromboprophylaxis Justified?
Thromb Haemost. 2020 Aug;120(8):1230-1232. doi: 10.1055/s-0040-1712097. Epub 2020 Apr 29.
10
Venous thromboembolism in patients with COVID-19 (SARS-CoV-2 infection) - a position paper of the German Society of Angiology (DGA).
Vasa. 2020 Jun;49(4):259-263. doi: 10.1024/0301-1526/a000885. Epub 2020 Jun 5.
本文引用的文献
1
Thromboprophylaxis in COVID-19: Anti-FXa-the Missing Factor?
Am J Respir Crit Care Med. 2020 Aug 1;202(3):455-457. doi: 10.1164/rccm.202005-1654LE.
2
Heparin-Related Major Bleeding in Covid-19-Positive Patient: Perspective from the Outbreak.
Cardiovasc Intervent Radiol. 2020 Aug;43(8):1216-1217. doi: 10.1007/s00270-020-02532-3. Epub 2020 May 28.
3
Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism?
Ann Intern Med. 2020 Sep 1;173(5):394-395. doi: 10.7326/M20-3255. Epub 2020 May 15.
4
Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.
J Thromb Haemost. 2020 Apr;18(4):844-847. doi: 10.1111/jth.14768. Epub 2020 Mar 13.
5
Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review.
Can J Hosp Pharm. 2015 Jan-Feb;68(1):33-47. doi: 10.4212/cjhp.v68i1.1423.
Zotero 插件